Bronchial asthma is an increasingly prevalent and often severe disease characterized by chronic inflammation of the airways, which is usually accompanied by increased vascular permeability, resulting in plasma exudation (1) . Changes in vascular permeability are crucial to the development and perpetuation of the inflammatory response. Increased vascular permeability causes secretion of intravascular components, which contribute to airway obstruction and hyperresponsiveness (2, 3) .
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogenic peptide and plays a key role in vasculogenesis and angiogenesis (4) . VEGF also stimulates vascular permeability, which leads to airway inflammation (3, 5, 6) . Recently, we demonstrated that VEGF is implicated in the pathogenesis of asthma, and thus the inhibition of VEGF receptor may be a good therapeutic strategy (3, 6, 7) . In addition, VEGF is a mediator of vascular and extravascular remodeling and inflammation that enhance antigen sensitization and is crucial in adaptive T-helper type 2 (Th2) cell-mediated inflammation (5) .
Mast cells are widely believed to contribute to the development of allergic airway disease. These cells are resident in tissues throughout the body and often are found in proximity to blood vessels, including capillaries and postcapillary venules (8) (9) (10) . Mast cells can be activated to release potent mediators of inflammation by antibody-dependent mechanisms, and can respond to very low doses of specific antigen (11, 12) . Although mast cells have been known to amplify inflammatory responses to antigen challenge, the molecular mechanism(s) by which these cells induce increased vascular permeability are not clearly understood.
In the present study, we used genetically mast cell-deficient and congenic normal mouse models of allergic airway disease to determine the role of mast cells, more specifically in the increase of vascular permeability. Some of the results of these studies have been previously reported in the form of an abstract (13) .
purchased from Japan SLC (Shizuoka, Japan). W/W v mice ordinarily contain less than 1.0% of the number of dermal mast cells present in the skin of the congenic normal WBB6F 1 1/1 mice and have no detectable mature mast cells in the respiratory system or other anatomic sites (14) (15) (16) . Mice were sensitized and challenged with ovalbumin (OVA) (Sigma-Aldrich Co., St. Louis, MO) as described previously with some modifications (17) . Mice were sensitized on Days 1 and 14 by intraperitoneal injection of 20 mg OVA. On Days 21, 22 , and 23 after the initial sensitization, the mice were challenged for 30 minutes with an aerosol of 3% (wt/vol) OVA in saline (or with saline as a control) using an ultrasonic nebulizer (NE-U12; Omron Corp., Tokyo, Japan). Bronchoalveolar lavage (BAL) was performed and smears of BAL cells were prepared with a cytospin (Thermo Electron, Waltham, MA).
Mast Cell Reconstitution
Selective reconstitution of mast cells in W/W v mice was performed by the method described by Williams and Galli (18) with slight modifications. Bone marrow cells of WBB6F 1 1/1 mice were cultured in RPMI (Roswell Park Memorial Institute) 1640 medium supplemented with 20% WEHI-3 condition medium (containing IL-3) for 4-5 weeks, at which time the cell populations were composed of more than 95% immature mast cells, as assessed by staining with May-Grü nwald-Giemsa solution. Bone marrow-derived cultured mast cells (BMCMCs; (5 3 10 6 ) were infused two times at 1-week intervals via the tail vein into each W/W v mouse. Fourteen weeks later, these reconstituted mice were immunized with OVA.
Administration of SU5614, SU1498, 2-Methoxyestradiol, LY-294002, or Wortmannin VEGF receptor inhibitor, SU5614 (2.5 mg/kg body weight per day; Calbiochem, San Diego, CA) or SU1498 (9 mg/kg body weight per day; Calbiochem) was administered intraperitoneally three times, beginning 1 hour before the first challenge. An inhibitor of hypoxia-inducible factor (HIF)-1a, 2-methoxyestradiol (2ME2) (100 mg/kg body weight per day; Sigma-Aldrich, St. Louis, MO) was administered by oral gavage six times, beginning 2 days before the first challenge (19) . LY-294002 (1.5 mg/kg body weight per day; BIOMOL Research Laboratories, Inc., Plymouth Meeting, PA) or wortmannin (100 mg/kg body weight per day; Calbiochem) was administered intratracheally two times, beginning 1 hour before the first challenge.
Western Blot Analysis
Protein expression levels were analyzed by Western blot analysis, as described previously (17) .
Measurement of Plasma Exudation
To assess lung permeability, Evans blue dye (EBD) was used as described previously (6) .
Histology, Immunohistochemistry, and Immunocytochemistry
Histologic examination and immunohistochemistry or immunocytochemistry of VEGF were performed as described previously (6) .
Measurements of Th2 Cytokines and VEGF in BAL Fluids
Levels of Th2 cytokines (IL-4, IL-5, and IL-13) and VEGF were quantified in the supernatants of BAL fluids by an enzyme immunoassay.
Determination of Airway Responsiveness
Airway responsiveness was assessed as a change in airway function after challenge with aerosolized methacholine via airways, as described elsewhere (20) . Under anesthesia, mice were tracheostomized and connected to a computer-controlled small-animal ventilator (flexiVent; SCIREQ, Montreal, PQ, Canada). Each mouse was challenged with methacholine aerosol in increasing concentrations (2.5-50 mg/ml in saline). After each methacholine challenge, data for respiratory system resistance (R rs ) were continuously collected. Maximum values of R rs were selected to express changes in airway function, which was represented as a percentage change from baseline after saline aerosol. 
Nuclear Protein Extractions for Analysis of HIF-1a
Nuclear extraction for analysis of HIF-1a was performed as described previously (21) .
Measurement of Phosphatidylinositol 3-Kinase Enzyme Activity in Lung Tissues
The amount of phosphatidylinositol-3,4,5-triphosphate (PIP3) produced was quantified by PIP3 competition enzyme immunoassays (17) .
Densitometric Analyses and Statistics
All immunoreactive and phosphorylative signals were analyzed by densitometric scanning (Gel Doc XR; Bio-Rad Laboratories, Inc., Hercules, CA). Data are expressed as mean 6 SEM. Statistical comparisons were performed using one-way analysis of variance followed by Scheffé 's test. Pearson's correlation was calculated to assess the correlation between data. Significant differences between two groups were determined using the unpaired Student's t test. Statistical significance was set at P , 0.05.
RESULTS

VEGF Protein Levels in Mice after OVA Inhalation
Western blot analysis revealed that levels of VEGF protein in the lung tissues were significantly increased at 48 hours after OVA inhalation compared with the levels in saline-sensitized and saline-challenged congenic normal WBB6F 1 1/1 mice, salinesensitized and saline-challenged mast cell-deficient W/W v mice, and saline-sensitized and saline-challenged mast cell-reconstituted W/W v mice (hereinafter referred to as BMCMC/W/W v mice). The levels of VEGF protein in the lung tissues of W/W v mice after OVA inhalation were significantly lower than the levels in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice and in OVA-sensitized and OVA-challenged BMCMC/ W/W v mice ( Figures 1A and 1B) . The levels of VEGF in OVAsensitized and OVA-challenged BMCMC/W/W v mice were similar to the levels in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice. Consistent with the results obtained from the Western blot analysis, enzyme immunoassays also showed that levels of VEGF protein in BAL fluids were significantly increased at 48 hours after OVA inhalation compared with levels in saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and salinechallenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/W/W v mice. The levels of VEGF protein in BAL fluids of W/W v mice after OVA inhalation were also significantly lower than in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice and in OVA-sensitized and OVA-challenged BMCMC/W/W v mice ( Figure 1C ). The levels of VEGF in OVA-sensitized and OVA-challenged BMCMC/W/W v mice were similar to the levels in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice.
Plasma Extravasation in Mice after OVA Inhalation
EBD assay revealed that plasma extravasation was significantly increased at 48 hours after OVA inhalation compared with the levels in saline-sensitized and saline-challenged WBB6F 1
mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/W/W v mice. However, the plasma extravasation in OVA-sensitized and OVAchallenged W/W v mice was significantly lower after OVA inhalation than the levels in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice ( Figure 1D ). On the other hand, the plasma extravasation in BMCMC/W/W v mice after OVA inhalation was similar to the levels in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice. In addition, the levels of VEGF protein in BAL fluids correlated significantly with the levels of plasma exudation in OVA-sensitized and OVA-challenged mice (r 5 0.889, P , 0.05) ( Figure 1E ).
Localization of Immunoreactive VEGF in Mice after OVA Inhalation
Immunohistochemical analysis showed localization of immunoreactive VEGF in inflammatory cells and epithelial layers around Figure 2K ) was less than that in the OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice and OVA-sensitized and OVA-challenged BMCMC/W/W v mice. Immunocytologic analysis of BAL fluids also revealed that immunoreactive VEGF staining was strong in macrophages, whereas immunoreactive VEGF was weakly stained in lymphocytes (see Figures E1A and E1B in the online supplement). When the expression of VEGF in BAL fluid eosinophils isolated by Percoll gradient centrifugation was examined, a low level of immunoreactive VEGF was observed (see Figure E1C ).
Cellular Changes in Mice after OVA Inhalation
Numbers of total cells, macrophages, lymphocytes, neutrophils, and eosinophils in BAL fluids were increased significantly at 48 hours after OVA inhalation compared with the numbers after saline inhalation ( Figure 3A) . However, the numbers of total cells, lymphocytes, neutrophils, and eosinophils in BAL fluids of OVA-sensitized and OVA-challenged W/W v mice were significantly lower after OVA inhalation than in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice ( Figure 3A ). On the other hand, numbers of total cells and eosinophils in BAL fluids of BMCMC/W/W v mice after OVA inhalation were significantly higher than in OVA-sensitized and OVA-challenged W/W v mice.
Pathologic Changes of OVA-induced Airway Disease
Histologic analyses revealed typical pathologic features of allergic airway disease in the OVA-exposed mice. Numerous inflammatory cells, including eosinophils, infiltrated around the bronchioles, and mucus and debris had accumulated in the lumen of bronchioles of OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice ( Figure 3E ) compared with the saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and salinechallenged BMCMC/W/W v mice ( Figures 3B-3D ). In contrast, no significant changes in the infiltration of inflammatory cells in the peribronchiolar region of saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/W/ W v mice were observed. The amount of mucus and debris in the airway lumen of W/W v mice was markedly reduced after OVA inhalation compared with that in OVA-sensitized and OVAchallenged WBB6F 1 1/1 mice ( Figure 3F ). The scores of peribronchial, perivascular, and total lung inflammation were increased significantly at 48 hours after OVA inhalation compared with those in saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/W/W v mice ( Figure 3H ). The inflammation scores of W/W v mice after OVA inhalation were significantly lower than those in OVA-sensitized and OVA-challenged 1/1 mice and in OVA-sensitized and OVA-challenged BMCMC/W/W v mice.
Airway Responsiveness in Mice after OVA Inhalation
In OVA-sensitized and OVA-challenged mice, the doseresponse curve of percent R rs shifted to the left compared with that of saline-sensitized and saline-challenged mice ( Figure 3I ). In addition, the R rs produced by methacholine administration (at doses ranging from 25 to 50 mg/ml) increased significantly in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice and OVA-sensitized and OVA-challenged BMCMC/W/W v mice compared with that in saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/ W/W v mice. The levels of R rs in OVA-sensitized and OVAchallenged W/W v mice were significantly lower at 50 mg/ml of methacholine inhalation than those in OVA-sensitized and OVAchallenged WBB6F 1 1/1 mice ( Figure 3I ). On the other hand, the levels of R rs in BMCMC/W/W v mice after OVA inhalation were significantly higher at 50 mg/ml of methacholine inhalation than in OVA-sensitized and OVA-challenged W/W v mice.
Th2 Cytokine Levels in Mice after OVA Inhalation
Western blot analysis revealed that IL-4, IL-5, and IL-13 protein levels in lung tissues were increased significantly at 48 hours after OVA inhalation compared with those in saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and salinechallenged BMCMC/W/W v mice ( Figures 4A and 4B) . However, the levels of IL-4, IL-5, and IL-13 protein in the lung tissues of W/W v mice after OVA inhalation were significantly lower than in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice. In contrast, the levels of IL-4, IL-5, and IL-13 protein in the lung tissues of BMCMC/W/W v mice after OVA inhalation were similar to those in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice. Consistent with these results, enzyme immunoassays also showed that levels of IL-4, IL-5, and IL-13 protein in BAL fluids were significantly increased after OVA inhalation compared with saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/W/W v mice ( Figure 4C ). The levels of IL-4, IL-5, and IL-13 protein in BAL fluids of W/W v mice after OVA inhalation were significantly lower than in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice. On the other hand, IL-4, IL-5, and IL-13 protein levels in BAL fluids of BMCMC/W/W v mice after OVA inhalation were significantly higher than in OVA-sensitized and OVA-challenged W/W v mice.
Effects of SU1498 on Changes in Cell Number and Th2
Cytokine Levels in BMCMC/W/W v Mice after OVA Inhalation
The increased numbers of total cells, lymphocytes, neutrophils, and eosinophils in BAL fluids of BMCMC/W/W v mice after OVA Figure 5A ). In addition, enzyme immunoassays showed that the increased levels of IL-4, IL-5, and IL-13 protein in BAL fluids of BMCMC/W/W v mice after OVA inhalation were significantly reduced by administration of SU1498 ( Figure 5B ).
Phosphatidylinositol 3-Kinase Enzyme Activity and Akt Phosphorylation in Mice after OVA Inhalation
We used Western blotting to determine the activation of Akt, which can activate the HIF pathway. Levels of phosphorylated Akt (p-Akt) protein in the lung tissues were significantly increased at 48 hours after OVA inhalation compared with the levels in saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/W/W v mice ( Figures 6A and 6B) . However, no significant changes in Akt protein levels were observed in any of the groups tested. The levels of p-Akt protein in the lung tissues of W/W v mice after OVA inhalation were significantly lower than the levels in OVAsensitized and OVA-challenged WBB6F 1 1/1 mice. On the other hand, the p-Akt protein levels in BMCMC/W/W v mice after OVA inhalation were significantly higher than the levels in OVAsensitized and OVA-challenged W/W v mice. In addition, we also measured phosphatidylinositol 3-kinase (PI3K) enzyme activity using the PIP3 competition enzyme immunoassay. PI3K activity in the lung tissues was increased after OVA inhalation compared with saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and saline-challenged W/W v mice, and salinesensitized and saline-challenged BMCMC/W/W v mice ( Figure  6C ). PI3K activity in the lung tissues of W/W v mice after OVA inhalation were significantly lower than the levels in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice, whereas the PI3K activity in BMCMC/W/W v mice after OVA inhalation was similar to the levels in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice.
HIF-1a Protein Levels in Mice after OVA Inhalation
Western blot analysis revealed that levels of HIF-1a in nuclear protein extracts from lung tissues were increased at 48 hours after OVA inhalation compared with the levels in saline-sensitized and saline-challenged WBB6F 1 1/1 mice, saline-sensitized and salinechallenged W/W v mice, and saline-sensitized and saline-challenged BMCMC/W/W v mice. The levels of HIF-1a protein in the lung tissues of W/W v mice after OVA inhalation were significantly lower than that in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice ( Figures 6D and 6E) , whereas the HIF-1a protein levels in BMCMC/W/W v mice after OVA inhalation were significantly higher than the levels in OVA-sensitized and OVA-challenged W/W v mice.
Effect of SU5614 or SU1498 on VEGF Levels, Akt Phosphorylation, and Plasma Extravasation in Mice after OVA Inhalation Western blot analysis revealed that the protein levels of VEGF and p-Akt in lung tissues of WBB6F 1 1/1 mice were increased significantly at 48 hours after OVA inhalation compared with levels after saline inhalation, and that administration of SU5614 or SU1498 dramatically reduced the increased levels of the proteins in lung tissues ( Figures 7A, 7B, 7D , and 7E). Consistent with these results, enzyme immunoassay showed that the administration of SU5614 or SU1498 reduced significantly the increased levels of VEGF in BAL fluids of WBB6F 1 1/1 mice after OVA inhalation ( Figure 7C ). In addition, EBD assay revealed that plasma extravasation was significantly increased at 48 hours after the last challenge. The increase in plasma extravasation was significantly reduced by the administration of SU5614 or SU1498 in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice ( Figure 7F ). These data suggest that vascular permeability is modulated by VEGF at least in part through PI3K signaling in allergic airway disease.
Effects of LY-294002 or Wortmannin on HIF-1a Levels in Mice after OVA Inhalation
Western blot analysis revealed that levels of HIF-1a in nuclear protein extracts from lung tissues of WBB6F 1 1/1 mice were increased at 48 hours after OVA inhalation compared with the levels after saline inhalation (Figure 8 ). The increased HIF-1a levels in nuclear protein extracts were decreased by the administration of LY-294002 or wortmannin in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice.
Effect of 2ME2 on HIF-1a and VEGF Protein Levels in Mice after OVA Inhalation
Western blot analysis showed that HIF-1a levels in nuclear extracts and VEGF protein levels in lung tissues of WBB6F 1 1/1 mice were increased significantly at 48 hours after OVA inhalation compared with the levels after saline inhalation. The increased VEGF levels after OVA inhalation were significantly reduced by the administration of 2ME2 (Figures 9A-9D ). Consistent with these results, enzyme immunoassays revealed that levels of VEGF in BAL fluids of WBB6F 1 1/1 mice were also increased significantly after OVA inhalation compared with the levels after saline inhalation ( Figure 9E ). The increased VEGF levels were significantly reduced by the administration of 2ME2 in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice.
Effects of PI3K Inhibitors and HIF-1a Inhibitor on Plasma Exudation in Mice after OVA Inhalation
EBD assay revealed that plasma extravasation was significantly increased at 48 hours after the last challenge. The increase in plasma extravasation was significantly reduced by the administration of LY294002 or wortmannin in OVA-sensitized and OVA-challenged WBB6F 1 1/1 mice (see Figure E2A ). In addition, the administration of 2ME2 reduced substantially the increase in plasma exudation after OVA inhalation (see Figure E2B ).
Relationship between VEGF Protein in BAL Fluids and Plasma Exudation
The changes of VEGF levels and plasma exudation were analyzed using an enzyme immunoassay and the EBD assay at 6, 12, 36, 24, 48, and 72 hours after a single OVA inhalation in OVAsensitized WBB6F 1 1/1 mice. The levels of VEGF protein in BAL fluids were increased significantly at 36, 48, and 72 hours after a single OVA inhalation compared with prechallenge levels (see Figure E3A ). EBD assay revealed that plasma exudation was significantly increased at 24, 36, 48, and 72 hours after a single OVA inhalation compared with prechallenge levels (see Figure E3B ). The levels of VEGF protein in BAL fluids correlated significantly with the levels of plasma exudation in OVA-sensitized WBB6F 1 1/1 mice with a single OVA challenge (r 5 0.608, P , 0.05) (see Figure E3C ).
DISCUSSION
Inflammation of the asthmatic airway is usually accompanied by increased vascular permeability and plasma exudation. Mast cells release a number of mediators that act directly on the vasculature to produce vasodilatation, increased permeability, and subsequent plasma protein extravasation into surrounding tissue (22) . VEGF has been implicated to contribute to asthmatic tissue edema through its effect on vascular permeability (23, 24) . However, the roles of mast cells in VEGF-mediated signaling in allergic airway disease are not clearly understood. We have used genetically mast cell-deficient mice to determine the role of mast cells, more specifically in the increase of vascular permeability.
Mast cells play a central role in the development of allergic respiratory disorders. IgE-dependent activation of mast cells can induce these cells to release a panel of preformed or newly synthesized mediators, including histamine, tryptase, prostaglandins, leukotrienes, platelet activating factor, and cytokines such as IL-4, IL-5, IL-13, and tumor necrosis factor-a, which can induce allergic reactions in the lung including airway obstruction, airway microvascular leakage, and mucosal edema, as well as mucus gland hypersecretion (25, 26) . Consistent with these findings, our data revealed that levels of Th2 cytokines, the number of inflammatory cells of the airways, and bronchial hyperresponsiveness in W/W v mice were significantly lower than those in WBB6F 1 1/1 mice after OVA inhalation. Moreover, reconstitution of mast cells in W/W v mice resulted in increases in levels of Th2 cytokines, the number of inflammatory cells of the airways, and bronchial hyperresponsiveness, which were similar to those of the WBB6F 1 1/1 mice. Mast cells can also produce and secrete VEGF upon stimulation through fragment crystallizable epsilon (Fce) receptor I or c-kit, or after challenge with the protein kinase C activator, phorbol myristate acetate, or the calcium ionophore A23187. The stimulated mast cells can rapidly release VEGF, apparently from a preformed pool, and can then sustain release by secreting newly synthesized protein (27) . In addition, VEGF can be produced by a wide variety of cells, which can be increased and recruited in airways by allergenic stimulation, including macrophages, neutrophils, eosinophils, and lymphocytes (3, 5, 6, 28, 29) . We have found that levels of VEGF in W/W v mice were significantly lower after OVA inhalation than the levels in OVA-induced WBB6F 1 1/1 mice. Moreover, reconstitution of mast cells in W/W v mice resulted in an increase in VEGF that was similar to those of the WBB6F 1 1/1 mice. Immunocytologic analysis has shown the localization of immunoreactive VEGF on macrophages, lymphocytes, and eosinophils in BAL cells from WBB6F 1 1/1 mice after OVA inhalation. Our present data also showed that the administration of VEGF receptor inhibitor SU1498 significantly reduced the increased numbers of inflammatory cells and the increased Th2 cytokines after OVA inhalation in BMCMC/W/W v mice. Taken together, these findings indicate that the mast cells may regulate airway inflammation and bronchial hyperresponsiveness through orchestrating VEGF expression in mast cells as well as the other inflammatory cells in allergic airway inflammation.
VEGF is a potent stimulator of inflammation, airway remodeling, and physiologic dysregulation that augments antigen sensitization and Th2 cell-mediated inflammation (5) . The major role of VEGF in asthma appears to be the enhancement of vascular permeability (3, 4, 6) . The mechanism of VEGFmediated induction of the vascular permeability seems to be the enhanced functional activity of vesicular/vacuolar organelles (4, 30) . Several studies have shown that overproduction of VEGF causes an increase in vascular permeability, which results in leakage of plasma proteins, including inflammatory mediators, and inflammatory cells into the extravascular space and allows migration of inflammatory cells into the airways (3, 6, 27) . Consistent with these observations, we have found that VEGF expression was up-regulated and vascular permeability was increased in OVA-induced allergic airway disease. Interestingly, plasma exudation in W/W v mice, which produce low levels of VEGF, was significantly lower after OVA inhalation than the levels in WBB6F 1 1/1 mice after OVA inhalation. Supporting the observations, BMCMC/W/W v mice exhibited increased levels of VEGF and increased vascular permeability that were similar to those of the WBB6F 1 1/1 mice after OVA inhalation. In addition, we have found that the levels of VEGF protein in BAL fluids correlated significantly with the levels of plasma exudation in OVA-sensitized and OVA-challenged mice and that the inhibition of VEGF activity reduced the plasma exudation in OVAsensitized and OVA-challenged WBB6F 1 1/1 mice. Taken together, these results suggest that the levels of VEGF are closely associated with vascular permeability, although the role of other contributing factors such as histamine cannot be excluded.
Several studies have indicated that PI3K plays a crucial role in VEGF-mediated signaling (31, 32) . In the present study, the administration of SU5614 or SU1498, which reduces the increased levels of VEGF in lungs, reduced dramatically the increased levels of p-Akt protein in lung tissues of WBB6F 1 1/1 mice after OVA inhalation. Previous reports have shown that increase of PI3K/Akt activity enhances the HIF signaling pathway (33) (34) (35) . Li and colleagues have also reported that activation of Akt turns on HIF-1a independently of hypoxia (36) . In the present study, levels of p-Akt protein and PI3K activity in the lung tissues were increased after OVA inhalation. On the other hand, levels of p-Akt and PI3K activity in W/W v mice were significantly lower after OVA inhalation than those in OVAinduced WBB6F 1 1/1 mice. BMCMC/W/W v mice exhibited increased p-Akt protein and PI3K activity that were similar to those of WBB6F 1 1/1 mice. In addition, the increased HIF-1a protein levels as well as plasma exudation were reduced significantly by the administration of PI3K inhibitor, LY-294002, or wortmannin in WBB6F 1 1/1 mice after OVA inhalation. VEGF expression is regulated through HIF-1a (37, 38) . Previous reports have demonstrated that HIF-1a plays a critical role in immune and inflammatory responses (39, 40) . Determination of HIF-1a protein level in nuclear extracts has revealed that this protein level was substantially increased in our present OVA-induced model of allergic airway disease, suggesting that HIF-1a was activated. However, levels of HIF-1a in W/W v mice were significantly lower after OVA inhalation than in OVAchallenged WBB6F 1 1/1 mice. To show the effects of HIF-1a inhibition on VEGF expression and vascular permeability, an HIF-1a inhibitor, 2ME2, was used. This inhibitor has been shown to inhibit HIF-1a activity through molecular mechanisms that suppress the HIF-1a translation and its nuclear translocation (19) . A previous study has demonstrated that the increased HIF1a protein levels after allergen inhalation were inhibited by the administration of 2ME2 (41) . In our study, the increased VEGF, vascular permeability, and HIF-1a protein levels after OVA inhalation were significantly decreased by administration of 2ME2. Taken together, we suggest that mast cell regulates HIF-1a action through a PI3K/Akt signaling pathway, resulting in increased VEGF expression in a murine model of allergic airway disease.
In this study, inhibitors of VEGF receptor tyrosine kinase, SU5614 and SU1498, were used to inhibit VEGF activity. Previous studies have demonstrated that administration of VEGF receptor inhibitors inhibits VEGF activity in a murine model of asthma (3, 6) . The increased leakage of plasma proteins and migration of inflammatory cells into the airways can be caused by the overproduction of VEGF (3, 6, 23) . In our previous study, the plasma leakage and the migration of inflammatory cells, which are the sources of VEGF production, were blocked by administration of SU5614 or SU1498, thereby reducing VEGF production (42) . In addition, there is a positive feedback loop with VEGF enhancing Th2 sensitization, inflammation, and cytokine elaboration and IL-13 subsequently enhancing VEGF production (5, 43) . Our previous data have also shown that inhibition of VEGF activity by administration of VEGF receptor inhibitors decreased Th2 inflammation, cytokine elaboration, and VEGF production in OVA-sensitized and OVA-challenged mice (42) . Consistent with these data, the increased numbers of inflammatory cells and the increased levels of Th2 cytokines after OVA inhalation were inhibited by the administration of SU1498 in our present study. Moreover, the autocrine action of VEGF has also been reported (44) . These findings suggest that VEGF receptor inhibitors can decrease VEGF production through inhibition of migration and inflammatory response of VEGF-producing cells or blocking of an autoinductive VEGF pathway.
SU5614 is a potent inhibitor of VEGF and platelet-derived growth factor (PDGF) receptor tyrosine kinases. It does not have any effect on the epidermal growth factor (EGF) and insulin-like growth factor (IGF) receptor tyrosine kinases. Previous studies have demonstrated that SU5614 also has inhibitory activity on other receptors such as c-kit and Flt-3 (45) (46) (47) . SU1498 is potent and selective inhibitor of Flk-1 kinase, a VEGF receptor kinase. It has only a weak inhibitory effect on PDGF receptor, EGF receptor, and human epidermal growth factor receptor-2 kinase. Therefore, the use of these two VEGF receptor inhibitors may rule out the inhibitory effects of these chemical inhibitors on other receptors.
In summary, we examined the role of mast cells in a murine model of allergic airway disease, more specifically in the increase of vascular permeability. By using genetically mast cell-deficient mice, we have shown that mast cells may regulate vascular leakage, at least in part, via modulation of the PI3K-HIF-1a-VEGF axis in mice.
